PTO- 1581 |
Approved for use through 12/31/2020. OMB 0651-0054 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
88751607 |
LAW OFFICE ASSIGNED |
LAW OFFICE 105 |
MARK SECTION |
MARK |
LIVIMMUNE (see, http://uspto.report/TM/88751607/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
LIVIMMUNE |
OWNER SECTION (current) |
NAME |
CytoDyn Inc. |
INTERNAL ADDRESS |
Suite 660 |
MAILING ADDRESS |
1111 Main Street |
CITY |
Vancouver |
STATE |
Washington |
ZIP/POSTAL CODE |
98660 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
OWNER SECTION (proposed) |
NAME |
CytoDyn Inc. |
INTERNAL ADDRESS |
Suite 660 |
MAILING ADDRESS |
1111 Main Street |
CITY |
Vancouver |
STATE |
Washington |
ZIP/POSTAL CODE |
98660 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
Jared M. Barrett |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
USTM.DOCKETING@SEEDIP.COM |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
Jared M. Barrett |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
USTM.DOCKETING@SEEDIP.COM |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
NOT PROVIDED |
DOCKET/REFERENCE NUMBER |
230042.205 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases,
nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer,
graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations,
namely, antibodies for use in targeting the CCR5 cell receptor |
GOODS OR SERVICES |
KEEP ALL LISTED |
INTERNATIONAL CLASS |
042 |
CURRENT IDENTIFICATION |
Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research
consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic
steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic
agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases
and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor |
GOODS OR SERVICES |
KEEP ALL LISTED |
INTERNATIONAL CLASS |
044 |
CURRENT IDENTIFICATION |
Providing health and medical information, and providing health and medical information in the nature of providing a website featuring
information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic
steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical
information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the
CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease,
autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19 |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
1 |
ALLOWANCE MAIL DATE |
08/04/2020 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
3 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
375 |
TOTAL AMOUNT |
375 |
SIGNATURE SECTION |
SIGNATURE |
/Jared M. Barrett/ |
SIGNATORY'S NAME |
Barrett, Jared M. |
SIGNATORY'S POSITION |
Attorney of record, Washington state Bar member |
DATE SIGNED |
01/08/2021 |
SIGNATORY'S PHONE NUMBER |
206-622-4900 |
SIGNATURE METHOD |
Sent to third party for signature |
FILING INFORMATION |
SUBMIT DATE |
Fri Jan 08 18:19:30 ET 2021 |
TEAS STAMP |
USPTO/ESU-XX.XXX.XXX.XXX-
20210108181930002198-8875
1607-76078ebc56039cfbddeb
2166b7f1ea3ae9473193ad2ed
e1b67176bdaad581251a60-CC
-19282124-202101081752178
71119 |
PTO- 1581 |
Approved for use through 12/31/2020. OMB 0651-0054 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: LIVIMMUNE (see, http://uspto.report/TM/88751607/mark.png)
SERIAL NUMBER: 88751607
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: CytoDyn Inc., having an address of
Suite 660
1111 Main Street
Vancouver, Washington 98660
United States
Email: XXXX
Proposed: CytoDyn Inc., having an address of
Suite 660
1111 Main Street
Vancouver, Washington 98660
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 08/04/2020.
For International Class 005:
Current identification: Therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis,
immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune
diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting
the CCR5 cell receptor
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
For International Class 042:
Current identification: Scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field
of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system
related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances
for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases
and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
For International Class 044:
Current identification: Providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic
agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases
and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in
targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in
the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune
system related diseases and disorders, respiratory diseases and disorders, COVID-19
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the first extension request.
Correspondence Information (current):
Jared M. Barrett
PRIMARY EMAIL FOR CORRESPONDENCE: USTM.DOCKETING@SEEDIP.COM
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Correspondence Information (proposed):
Jared M. Barrett
PRIMARY EMAIL FOR CORRESPONDENCE: USTM.DOCKETING@SEEDIP.COM
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $375 will be submitted with the form, representing payment for 3 classes.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Jared M. Barrett/ Date Signed: 01/08/2021
Signatory's Name: Barrett, Jared M.
Signatory's Position: Attorney of record, Washington state Bar member
Signatory's Phone: 206-622-4900
Signature method: Sent to third party for signature
PAYMENT: 88751607
PAYMENT DATE: 01/08/2021
Serial Number: 88751607
Internet Transmission Date: Fri Jan 08 18:19:30 ET 2021
TEAS Stamp: USPTO/ESU-XX.XXX.XXX.XXX-202101081819300
02198-88751607-76078ebc56039cfbddeb2166b
7f1ea3ae9473193ad2ede1b67176bdaad581251a
60-CC-19282124-20210108175217871119